person · Reporting owner

Khattar Jack A.

Disclosed activity across 3 companies

Tapewire entity: 23273
SEC CIK: 0001539937

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
COGNITION THERAPEUTICS INCCGTX · Entity 6792	Director	June 17, 2026	June 22, 2026
SUPERNUS PHARMACEUTICALS, INC.SUPN · Entity 4333	Director · President, CEO	August 12, 2026	August 14, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

COGNITION THERAPEUTICS INC

Report date June 17, 2026 · Filed June 22, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	73,500	Reported balance After 2026-06-17 transaction · row 1 1 source row Row 1 · 2026-06-17 · Grant · Acquired 25,000 · Balance 73,500 F1: Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. The RSUs vest in full on the earlier of (i) June 17, 2027 or (ii) on the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service as a director as of the applicable vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. The RSUs vest in full on the earlier of (i) June 17, 2027 or (ii) on the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service as a director as of the applicable vesting date.

SUPERNUS PHARMACEUTICALS, INC.

Report date August 12, 2026 · Filed August 14, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	1,258,351	Ending reported balance After 2026-08-12 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2026-08-12 · Exercise / conversion · Acquired 29,849 · Balance 1,270,993 Row 2 · 2026-08-12 · Tax withholding · Disposed 12,642 · Balance 1,258,351 F1: Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the vesting of Performance Share Units.
Performance Share UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	0	Reported balance After 2026-08-12 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2026-08-12 · Exercise / conversion · Disposed 29,849 · Balance 0 F2: On February 19, 2025, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on May 3, 2025.
Common StockSEC Table I · non-derivative	IndirectBy the KBT Trust	958,100	Reported balance Holding disclosure · report date 2026-08-12 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 958,100

Filing footnotes · ownership attribution and instrument terms

F1: Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the vesting of Performance Share Units.

F2: On February 19, 2025, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on May 3, 2025.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

scPharmaceuticals Inc.

Report date October 07, 2025 · Filed October 07, 2025

Section 16 reporting ended · disclosed 2025-10-07. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2025-10-07 transaction · row 1 1 source row Row 1 · 2025-10-07 · Other · Disposed 5,000 · Balance 0 F1: In connection with the terms of an Agreement and Plan of Merger, dated as of August 24, 2025 (the "Merger Agreement"), by and among the Issuer, MannKind Corporation ("Parent") and Seacoast Merger Sub, Inc., a direct wholly owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's common stock ("Common Stock") on October 7, 2025. Tendering stockholders received per share consideration of $5.35 in cash, without interest, subject to any applicable withholding taxes, plus one non-tradable contingent value right ("CVR"), representing the right to receive certain contingent payments of up to an aggregate amount of $1.00 per CVR in cash, F2: (Continued from footnote 1) without interest, subject to any applicable withholding taxes, upon the achievement of certain regulatory and net sales milestones on or prior to the applicable milestone outside dates. After completion of the tender offer, Purchaser merged with and into the Issuer (the "Merger", and the effective time of the Merger, the "Effective Time"), with the Issuer continuing as the surviving corporation in the Merger and a wholly owned subsidiary of Parent.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.85 · Expires 2035-06-03	Direct	Reported balance After 2025-10-07 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2025-10-07 · Disposition to issuer · Disposed 30,000 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time and that had an exercise price per share that was less than $5.35, whether or not then vested or exercisable, was cancelled and converted into the right to receive (i) an amount in cash, without interest and subject to any applicable withholding taxes, equal to (A) the total number of shares subject to such Company Option immediately prior to such cancellation multiplied by (B) the excess, if any, of (x) $5.35 over (y) the exercise price payable per share underlying such Company Option and (ii) one CVR in respect of each share subject to such Company Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.11 · Expires 2034-06-11	Direct	Reported balance After 2025-10-07 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2025-10-07 · Disposition to issuer · Disposed 19,750 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time and that had an exercise price per share that was less than $5.35, whether or not then vested or exercisable, was cancelled and converted into the right to receive (i) an amount in cash, without interest and subject to any applicable withholding taxes, equal to (A) the total number of shares subject to such Company Option immediately prior to such cancellation multiplied by (B) the excess, if any, of (x) $5.35 over (y) the exercise price payable per share underlying such Company Option and (ii) one CVR in respect of each share subject to such Company Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.53 · Expires 2032-06-14	Direct	Reported balance After 2025-10-07 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2025-10-07 · Disposition to issuer · Disposed 16,300 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time and that had an exercise price per share that was less than $5.35, whether or not then vested or exercisable, was cancelled and converted into the right to receive (i) an amount in cash, without interest and subject to any applicable withholding taxes, equal to (A) the total number of shares subject to such Company Option immediately prior to such cancellation multiplied by (B) the excess, if any, of (x) $5.35 over (y) the exercise price payable per share underlying such Company Option and (ii) one CVR in respect of each share subject to such Company Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.37 · Expires 2029-06-18	Direct	Reported balance After 2025-10-07 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2025-10-07 · Disposition to issuer · Disposed 6,124 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time and that had an exercise price per share that was less than $5.35, whether or not then vested or exercisable, was cancelled and converted into the right to receive (i) an amount in cash, without interest and subject to any applicable withholding taxes, equal to (A) the total number of shares subject to such Company Option immediately prior to such cancellation multiplied by (B) the excess, if any, of (x) $5.35 over (y) the exercise price payable per share underlying such Company Option and (ii) one CVR in respect of each share subject to such Company Option.

Filing footnotes · ownership attribution and instrument terms

F1: In connection with the terms of an Agreement and Plan of Merger, dated as of August 24, 2025 (the "Merger Agreement"), by and among the Issuer, MannKind Corporation ("Parent") and Seacoast Merger Sub, Inc., a direct wholly owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's common stock ("Common Stock") on October 7, 2025. Tendering stockholders received per share consideration of $5.35 in cash, without interest, subject to any applicable withholding taxes, plus one non-tradable contingent value right ("CVR"), representing the right to receive certain contingent payments of up to an aggregate amount of $1.00 per CVR in cash,

F2: (Continued from footnote 1) without interest, subject to any applicable withholding taxes, upon the achievement of certain regulatory and net sales milestones on or prior to the applicable milestone outside dates. After completion of the tender offer, Purchaser merged with and into the Issuer (the "Merger", and the effective time of the Merger, the "Effective Time"), with the Issuer continuing as the surviving corporation in the Merger and a wholly owned subsidiary of Parent.

F3: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time and that had an exercise price per share that was less than $5.35, whether or not then vested or exercisable, was cancelled and converted into the right to receive (i) an amount in cash, without interest and subject to any applicable withholding taxes, equal to (A) the total number of shares subject to such Company Option immediately prior to such cancellation multiplied by (B) the excess, if any, of (x) $5.35 over (y) the exercise price payable per share underlying such Company Option and (ii) one CVR in respect of each share subject to such Company Option.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
January 31, 2023 Filed Feb 2, 2023 22:00 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	Exercise / conversionCommon Stock	1,620	$9.56	$15,487.20	Disclosure SEC source: 0001104659-23-009959 · tm235112-1_4seq1.xml · nonDerivative · entry 1 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 795,937 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 15, 2022. Read SEC document
January 18, 2023 Filed Jan 20, 2023 22:00 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative	8,080	$0.00 Strike: $9.56	$0.00	Disclosure SEC source: 0001104659-23-005449 · tm233672-6_4seq1.xml · derivative · entry 4 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 8,080 shares Expires 2024-01-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 15, 2022. F3 · derivative.exercise_date: The options vested in four equal annual installments beginning on January 23, 2015. Read SEC document
January 18, 2023 Filed Jan 20, 2023 22:00 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	SaleCommon Stock	4,936	$40.40	$199,394.16	Disclosure SEC source: 0001104659-23-005449 · tm233672-6_4seq1.xml · nonDerivative · entry 2 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 794,317 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 15, 2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.01 to $40.68, inclusive. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document
January 18, 2023 Filed Jan 20, 2023 22:00 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	Exercise / conversionCommon Stock	8,080	$9.56	$77,244.80	Disclosure SEC source: 0001104659-23-005449 · tm233672-6_4seq1.xml · nonDerivative · entry 1 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 799,253 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 15, 2022. Read SEC document
January 17, 2023 Filed Jan 19, 2023 22:00 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative	41,920	$0.00 Strike: $9.56	$0.00	Disclosure SEC source: 0001104659-23-005057 · tm233672-5_4seq1.xml · derivative · entry 4 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,080 Underlying: Common Stock · 41,920 shares Expires 2024-01-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 15, 2022. F3 · derivative.exercise_date: The options vested in four equal annual installments beginning on January 23, 2015. Read SEC document
January 17, 2023 Filed Jan 19, 2023 22:00 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	SaleCommon Stock	25,446	$40.03	$1,018,728.07	Disclosure SEC source: 0001104659-23-005057 · tm233672-5_4seq1.xml · nonDerivative · entry 2 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 791,173 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 15, 2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.11, inclusive. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document
January 17, 2023 Filed Jan 19, 2023 22:00 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	Exercise / conversionCommon Stock	41,920	$9.56	$400,755.20	Disclosure SEC source: 0001104659-23-005057 · tm233672-5_4seq1.xml · nonDerivative · entry 1 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 816,619 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 15, 2022. Read SEC document
December 21, 2022 Filed Dec 22, 2022 22:00 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	SaleCommon Stock	11,354	$38.14	$433,069.95	Disclosure SEC source: 0001104659-22-129580 · tm2233271-1_4seq1.xml · nonDerivative · entry 5 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 814,699 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 15, 2022. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.00 to $38.38, inclusive. The Reporting Person undertakes to provide to Supernus, any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document
December 21, 2022 Filed Dec 22, 2022 22:00 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	Exercise / conversionCommon Stock	18,472	$9.56	$176,592.32	Disclosure SEC source: 0001104659-22-129580 · tm2233271-1_4seq1.xml · nonDerivative · entry 4 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 826,053 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 15, 2022. Read SEC document
December 21, 2022 Filed Dec 22, 2022 22:00 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	GrantCommon Stock	15,625	$0.00	$0.00	Disclosure SEC source: 0001104659-22-129580 · tm2233271-1_4seq1.xml · nonDerivative · entry 3 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 807,581 F3 · price: Shares of common stock received upon the settlement of certain performance share units granted to the Reporting Person on February 21, 2020. Read SEC document
December 20, 2022 Filed Dec 22, 2022 22:00 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative	18,472	$0.00 Strike: $9.56	$0.00	Disclosure SEC source: 0001104659-22-129580 · tm2233271-1_4seq1.xml · derivative · entry 8 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 18,472 shares Expires 2024-01-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 15, 2022. F6 · derivative.exercise_date: The options vested in four equal annual installments beginning on January 23, 2015. Read SEC document
December 20, 2022 Filed Dec 22, 2022 22:00 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative	6,528	$0.00 Strike: $9.56	$0.00	Disclosure SEC source: 0001104659-22-129580 · tm2233271-1_4seq1.xml · derivative · entry 7 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,472 Underlying: Common Stock · 6,528 shares Expires 2024-01-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 15, 2022. F6 · derivative.exercise_date: The options vested in four equal annual installments beginning on January 23, 2015. Read SEC document
December 20, 2022 Filed Dec 22, 2022 22:00 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	SaleCommon Stock	4,006	$38.02	$152,316.93	Disclosure SEC source: 0001104659-22-129580 · tm2233271-1_4seq1.xml · nonDerivative · entry 2 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 791,956 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 15, 2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.00 to $38.09, inclusive. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document
December 20, 2022 Filed Dec 22, 2022 22:00 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	Exercise / conversionCommon Stock	6,528	$9.56	$62,407.68	Disclosure SEC source: 0001104659-22-129580 · tm2233271-1_4seq1.xml · nonDerivative · entry 1 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 795,962 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 15, 2022. Read SEC document
November 25, 2022 Filed Nov 28, 2022 22:02 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative	17,794	$0.00 Strike: $9.56	$0.00	Disclosure SEC source: 0001104659-22-122479 · tm2231406-1_4seq1.xml · derivative · entry 8 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 17,794 shares Expires 2024-01-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 15, 2022. F5 · derivative.exercise_date: The options vested in four equal annual installments beginning on January 23, 2015. Read SEC document
November 25, 2022 Filed Nov 28, 2022 22:02 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	SaleCommon Stock	11,135	$35.18	$391,684.76	Disclosure SEC source: 0001104659-22-122479 · tm2231406-1_4seq1.xml · nonDerivative · entry 4 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 789,434 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 15, 2022. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.00 to $35.36, inclusive. The Reporting Person undertakes to provide to Supernus, any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document
November 25, 2022 Filed Nov 28, 2022 22:02 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	Exercise / conversionCommon Stock	17,794	$9.56	$170,110.64	Disclosure SEC source: 0001104659-22-122479 · tm2231406-1_4seq1.xml · nonDerivative · entry 3 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 800,569 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 15, 2022. Read SEC document
November 23, 2022 Filed Nov 28, 2022 22:02 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative	3,616	$0.00 Strike: $9.56	$0.00	Disclosure SEC source: 0001104659-22-122479 · tm2231406-1_4seq1.xml · derivative · entry 7 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,794 Underlying: Common Stock · 3,616 shares Expires 2024-01-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 15, 2022. F5 · derivative.exercise_date: The options vested in four equal annual installments beginning on January 23, 2015. Read SEC document
November 23, 2022 Filed Nov 28, 2022 22:02 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	SaleCommon Stock	2,259	$35.05	$79,188.79	Disclosure SEC source: 0001104659-22-122479 · tm2231406-1_4seq1.xml · nonDerivative · entry 2 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 782,775 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 15, 2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.00 to $35.23, inclusive. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document
November 23, 2022 Filed Nov 28, 2022 22:02 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	Exercise / conversionCommon Stock	3,616	$9.56	$34,568.96	Disclosure SEC source: 0001104659-22-122479 · tm2231406-1_4seq1.xml · nonDerivative · entry 1 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 785,034 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 15, 2022. Read SEC document
November 22, 2022 Filed Nov 23, 2022 22:00 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative	959	$0.00 Strike: $9.56	$0.00	Disclosure SEC source: 0001104659-22-121796 · tm2231250-1_4seq1.xml · derivative · entry 5 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,410 Underlying: Common Stock · 959 shares Expires 2024-01-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 15, 2022. F4 · derivative.exercise_date: The options vested in four equal annual installments beginning on January 23, 2015. Read SEC document
November 22, 2022 Filed Nov 23, 2022 22:00 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	SaleCommon Stock	600	$35.00	$21,001.08	Disclosure SEC source: 0001104659-22-121796 · tm2231250-1_4seq1.xml · nonDerivative · entry 2 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 781,418 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 15, 2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.00 to $35.02, inclusive. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document
November 22, 2022 Filed Nov 23, 2022 22:00 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	Exercise / conversionCommon Stock	959	$9.56	$9,168.04	Disclosure SEC source: 0001104659-22-121796 · tm2231250-1_4seq1.xml · nonDerivative · entry 1 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 782,018 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 15, 2022. Read SEC document
November 21, 2022 Filed Nov 22, 2022 22:00 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative	848	$0.00 Strike: $9.56	$0.00	Disclosure SEC source: 0001104659-22-121285 · tm2231147-1_4seq1.xml · derivative · entry 5 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,369 Underlying: Common Stock · 848 shares Expires 2024-01-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 15, 2022. F4 · derivative.exercise_date: The options vested in four equal annual installments beginning on January 23, 2015. Read SEC document
November 21, 2022 Filed Nov 22, 2022 22:00 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	SaleCommon Stock	531	$35.01	$18,592.22	Disclosure SEC source: 0001104659-22-121285 · tm2231147-1_4seq1.xml · nonDerivative · entry 2 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 781,059 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 15, 2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.00 to $35.04, inclusive. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document
November 21, 2022 Filed Nov 22, 2022 22:00 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	Exercise / conversionCommon Stock	848	$9.56	$8,106.88	Disclosure SEC source: 0001104659-22-121285 · tm2231147-1_4seq1.xml · nonDerivative · entry 1 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 781,590 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 15, 2022. Read SEC document
November 15, 2022 Filed Nov 17, 2022 22:00 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative	1,783	$0.00 Strike: $9.56	$0.00	Disclosure SEC source: 0001104659-22-119930 · tm2230682-1_4seq1.xml · derivative · entry 5 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,217 Underlying: Common Stock · 1,783 shares Expires 2024-01-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 15, 2022. F4 · derivative.exercise_date: The options vested in four equal annual installments beginning on January 23, 2015. Read SEC document
November 15, 2022 Filed Nov 17, 2022 22:00 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	SaleCommon Stock	1,115	$35.00	$39,028.01	Disclosure SEC source: 0001104659-22-119930 · tm2230682-1_4seq1.xml · nonDerivative · entry 2 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 780,742 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 15, 2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.00 to $35.03, inclusive. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document
November 15, 2022 Filed Nov 17, 2022 22:00 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	Exercise / conversionCommon Stock	1,783	$9.56	$17,045.48	Disclosure SEC source: 0001104659-22-119930 · tm2230682-1_4seq1.xml · nonDerivative · entry 1 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 781,857 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 15, 2022. Read SEC document
September 14, 2022 Filed Sep 15, 2022 21:15 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	Exercise / conversionStock Appreciation Right · Derivative	5,895	$0.00 Strike: $7.90	$0.00	Disclosure SEC source: 0001104659-22-100486 · tm2225575-1_4seq1.xml · derivative · entry 5 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,895 shares Expires 2023-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The SAR vested in four equal annual installments beginning on February 5, 2014. Read SEC document
September 14, 2022 Filed Sep 15, 2022 21:15 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	Exercise / conversionCommon Stock	1,380	$33.75	$46,575.00	Disclosure SEC source: 0001104659-22-100486 · tm2225575-1_4seq1.xml · nonDerivative · entry 2 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 780,074 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Pursuant to the terms of the stock appreciation right ("SAR"), upon settlement of the SAR the Reporting Person is entitled to receive shares of common stock in an amount equal to the excess of the fair market value of the common stock on the date of exercise over the base value per share of common stock established at the time the SAR was granted. This transaction reports the number of shares of common stock equal to the difference between the number of shares underlying the exercised SAR and the number of shares issued to the Reporting Person. F2 · price: The price reported in Column 4 is the closing price of the common stock on August 29, 2022, the date of the SAR's exercise, as reported by NASDAQ Stock Market, LLC. Read SEC document
September 14, 2022 Filed Sep 15, 2022 21:15 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	Exercise / conversionCommon Stock	5,895	$0.00	$0.00	Disclosure SEC source: 0001104659-22-100486 · tm2225575-1_4seq1.xml · nonDerivative · entry 1 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 781,454 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
August 16, 2022 Filed Aug 18, 2022 21:15 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	Exercise / conversionStock Appreciation Right · Derivative	39,530	$0.00 Strike: $7.90	$0.00	Disclosure SEC source: 0001104659-22-092614 · tm2223647-2_4seq1.xml · derivative · entry 6 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,895 Underlying: Common Stock · 39,530 shares Expires 2023-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted June 12, 2022. F5 · derivative.exercise_date: The stock appreciation right vested in four equal annual installments beginning on February 5, 2014. Read SEC document
August 16, 2022 Filed Aug 18, 2022 21:15 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	SaleCommon Stock	14,690	$34.01	$499,650.97	Disclosure SEC source: 0001104659-22-092614 · tm2223647-2_4seq1.xml · nonDerivative · entry 3 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 775,559 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted June 12, 2022. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.00 to $34.07, inclusive. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4. Read SEC document
August 16, 2022 Filed Aug 18, 2022 21:15 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	Exercise / conversionCommon Stock	9,182	$34.01	$312,307.37	Disclosure SEC source: 0001104659-22-092614 · tm2223647-2_4seq1.xml · nonDerivative · entry 2 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 790,249 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Pursuant to the terms of the stock appreciation right ("SAR"), upon settlement of the SAR the Reporting Person is entitled to receive shares of common stock in an amount equal to the excess of the fair market value of the common stock on the date of exercise over the base value per share of common stock established at the time the SAR was granted. This transaction reports the number of shares of common stock equal to the difference between the number of shares underlying the exercised SAR and the number of shares issued to the Reporting Person. F2 · shares: Pursuant to the terms of the stock appreciation right ("SAR"), upon settlement of the SAR the Reporting Person is entitled to receive shares of common stock in an amount equal to the excess of the fair market value of the common stock on the date of exercise over the base value per share of common stock established at the time the SAR was granted. This transaction reports the number of shares of common stock equal to the difference between the number of shares underlying the exercised SAR and the number of shares issued to the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.00 to $34.07, inclusive. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4. Read SEC document
August 16, 2022 Filed Aug 18, 2022 21:15 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	Exercise / conversionCommon Stock	39,530	$0.00	$0.00	Disclosure SEC source: 0001104659-22-092614 · tm2223647-2_4seq1.xml · nonDerivative · entry 1 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 799,431 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted June 12, 2022. F1 · price: Transaction made pursuant to a 10b5-1 trading plan adopted June 12, 2022. Read SEC document
August 15, 2022 Filed Aug 17, 2022 20:27 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	Exercise / conversionStock Appreciation Right · Derivative	46,575	$0.00 Strike: $7.90	$0.00	Disclosure SEC source: 0001104659-22-092204 · tm2223647-1_4seq1.xml · derivative · entry 6 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,425 Underlying: Common Stock · 46,575 shares Expires 2023-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted June 12, 2022. F5 · derivative.exercise_date: The stock appreciation right vested in four equal annual installments beginning on February 5, 2014. Read SEC document
August 15, 2022 Filed Aug 17, 2022 20:27 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	SaleCommon Stock	17,302	$34.03	$588,752.46	Disclosure SEC source: 0001104659-22-092204 · tm2223647-1_4seq1.xml · nonDerivative · entry 3 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 759,901 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted June 12, 2022. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.00 to $34.13, inclusive. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4. Read SEC document
August 15, 2022 Filed Aug 17, 2022 20:27 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	Exercise / conversionCommon Stock	10,813	$34.03	$367,944.76	Disclosure SEC source: 0001104659-22-092204 · tm2223647-1_4seq1.xml · nonDerivative · entry 2 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 777,203 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Pursuant to the terms of the stock appreciation right ("SAR"), upon settlement of the SAR the Reporting Person is entitled to receive shares of common stock in an amount equal to the excess of the fair market value of the common stock on the date of exercise over the base value per share of common stock established at the time the SAR was granted. This transaction reports the number of shares of common stock equal to the difference between the number of shares underlying the exercised SAR and the number of shares issued to the Reporting Person. F2 · shares: Pursuant to the terms of the stock appreciation right ("SAR"), upon settlement of the SAR the Reporting Person is entitled to receive shares of common stock in an amount equal to the excess of the fair market value of the common stock on the date of exercise over the base value per share of common stock established at the time the SAR was granted. This transaction reports the number of shares of common stock equal to the difference between the number of shares underlying the exercised SAR and the number of shares issued to the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.00 to $34.13, inclusive. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4. Read SEC document
August 15, 2022 Filed Aug 17, 2022 20:27 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	Exercise / conversionCommon Stock	46,575	$0.00	$0.00	Disclosure SEC source: 0001104659-22-092204 · tm2223647-1_4seq1.xml · nonDerivative · entry 1 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 788,016 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted June 12, 2022. F1 · price: Transaction made pursuant to a 10b5-1 trading plan adopted June 12, 2022. Read SEC document
August 10, 2022 Filed Aug 11, 2022 21:15 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative	44,900	$0.00 Strike: $7.90	$0.00	Disclosure SEC source: 0001104659-22-089438 · tm2222645-5_4seq1.xml · derivative · entry 5 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 44,900 shares Expires 2023-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option vested in four equal annual installments beginning on February 5, 2014. Read SEC document
August 10, 2022 Filed Aug 11, 2022 21:15 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	SaleCommon Stock	28,437	$31.22	$887,803.14	Disclosure SEC source: 0001104659-22-089438 · tm2222645-5_4seq1.xml · nonDerivative · entry 2 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 741,441 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted June 12, 2022. F1 · price: Transaction made pursuant to a 10b5-1 trading plan adopted June 12, 2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.00 to $31.51, inclusive. The reporting person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document
August 10, 2022 Filed Aug 11, 2022 21:15 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	Exercise / conversionCommon Stock	44,900	$0.00	$0.00	Disclosure SEC source: 0001104659-22-089438 · tm2222645-5_4seq1.xml · nonDerivative · entry 1 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 769,878 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted June 12, 2022. F1 · price: Transaction made pursuant to a 10b5-1 trading plan adopted June 12, 2022. Read SEC document
August 09, 2022 Filed Aug 10, 2022 21:25 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative	63,100	$0.00 Strike: $7.90	$0.00	Disclosure SEC source: 0001104659-22-088700 · tm2222645-4_4seq1.xml · derivative · entry 5 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,900 Underlying: Common Stock · 63,100 shares Expires 2023-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option vested in four equal annual installments beginning on February 5, 2014. Read SEC document
August 09, 2022 Filed Aug 10, 2022 21:25 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	SaleCommon Stock	39,431	$31.15	$1,228,275.65	Disclosure SEC source: 0001104659-22-088700 · tm2222645-4_4seq1.xml · nonDerivative · entry 2 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 724,978 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted June 12, 2022. F1 · price: Transaction made pursuant to a 10b5-1 trading plan adopted June 12, 2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.00 to $31.64, inclusive. The reporting person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document
August 09, 2022 Filed Aug 10, 2022 21:25 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	Exercise / conversionCommon Stock	63,100	$0.00	$0.00	Disclosure SEC source: 0001104659-22-088700 · tm2222645-4_4seq1.xml · nonDerivative · entry 1 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 764,409 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted June 12, 2022. F1 · price: Transaction made pursuant to a 10b5-1 trading plan adopted June 12, 2022. Read SEC document
August 08, 2022 Filed Aug 9, 2022 21:25 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative	192,000	$0.00 Strike: $7.90	$0.00	Disclosure SEC source: 0001104659-22-088044 · tm2222645-3_4seq1.xml · derivative · entry 6 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,000 Underlying: Common Stock · 192,000 shares Expires 2023-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option vested in four equal annual installments beginning on February 5, 2014. Read SEC document
August 08, 2022 Filed Aug 9, 2022 21:25 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	SaleCommon Stock	10,032	$32.11	$322,127.52	Disclosure SEC source: 0001104659-22-088044 · tm2222645-3_4seq1.xml · nonDerivative · entry 3 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 701,309 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted June 12, 2022. F1 · price: Transaction made pursuant to a 10b5-1 trading plan adopted June 12, 2022. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.960 to $32.535, inclusive. The reporting person undertakes to provide to Supernus, any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4. Read SEC document
August 08, 2022 Filed Aug 9, 2022 21:25 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	SaleCommon Stock	107,875	$31.40	$3,387,275.00	Disclosure SEC source: 0001104659-22-088044 · tm2222645-3_4seq1.xml · nonDerivative · entry 2 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 711,341 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted June 12, 2022. F1 · price: Transaction made pursuant to a 10b5-1 trading plan adopted June 12, 2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.950 to $31.950, inclusive. The reporting person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document
August 08, 2022 Filed Aug 9, 2022 21:25 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	Exercise / conversionCommon Stock	192,000	$0.00	$0.00	Disclosure SEC source: 0001104659-22-088044 · tm2222645-3_4seq1.xml · nonDerivative · entry 1 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 819,216 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted June 12, 2022. F1 · price: Transaction made pursuant to a 10b5-1 trading plan adopted June 12, 2022. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.